NEUROFARBA Department, Pharmaceutical and Nutraceutical Section and Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Via U. Schiff 6, Sesto Fiorentino, Florence 50019, Italy.
Research Institute of the University of Bucharest (ICUB), Bucharest 050663, Romania.
J Med Chem. 2024 Jun 13;67(11):9613-9627. doi: 10.1021/acs.jmedchem.4c00740. Epub 2024 May 22.
The development of antibacterial drugs with new mechanisms of action is crucial in combating the rise of antibiotic-resistant infections. Bacterial carbonic anhydrases (CAs, EC 4.2.1.1) have been validated as promising antibacterial targets against pathogens such as , , and vancomycin-resistant enterococci. A multitarget strategy is proposed to design penicillin-based CA inhibitor hybrids for tackling resistance by targeting multiple bacterial pathways, thereby resensitizing drug-resistant strains to clinical antibiotics. The sulfonamide derivatives potently inhibited the CAs from and with values in the range of 7.1-617.2 nM. Computational simulations with the main penicillin-binding protein (PBP) of indicated that these hybrid derivatives maintained the mechanism of action of the lead β-lactams. A subset of derivatives showed potent PBP-related antigonococcal effects against multidrug-resistant strains, with several compounds significantly outperforming both the lead β-lactam and CA inhibitor drugs (MIC values in the range 0.25 to 0.5 μg/mL).
新型抗菌药物的开发对于对抗抗生素耐药性感染至关重要。细菌碳酸酐酶(CA,EC 4.2.1.1)已被验证为一种有前途的抗菌靶点,可针对 、 和耐万古霉素肠球菌等病原体。提出了一种多靶标策略来设计基于青霉素的 CA 抑制剂杂合化合物,以通过靶向多个细菌途径来解决耐药性问题,从而使耐药菌株对临床抗生素重新敏感。磺胺衍生物对 和 的 CA 具有很强的抑制作用, 值范围为 7.1-617.2 nM。与 的主要青霉素结合蛋白(PBP)的计算模拟表明,这些杂合衍生物保持了先导β-内酰胺的作用机制。一组衍生物对多药耐药 株具有很强的与 PBP 相关的抗淋病效果,其中几种化合物的表现明显优于先导β-内酰胺和 CA 抑制剂药物(MIC 值范围为 0.25 至 0.5 μg/mL)。